Fistura® Procedure for the Treatment of Complex Anal Fistulas

October 2, 2023 updated by: Dr Benjamin NEBBOT

Radiofrequency Using the Fistura® Procedure for the Treatment of Complex Anal Fistulas: Assessing Healing Rate and Anal Incontinence up to 1 Year Follow-up

This study aims to evaluate the healing rate of complex fistulas using radiofrequency (Fistura® procedure), in a prospective, interventional, monocenter, single-arm design.

Study Overview

Status

Suspended

Intervention / Treatment

Detailed Description

Perianal fistula is a rare disease characterized by a tract that connects the perineal skin to the anal canal. These fistulas usually lead to anal pain, intermittent anal purulent discharge and abscess recurrence. The choice of the treatment depends on the type of fistula, simple or complex fistulas. Simple fistulas are defined as inter-sphincteric and trans-sphincteric fistulas involving less than 30 % of the external sphincter. Complex anal fistulas include trans-sphincteric fistulas involving more than 30% of the external sphincter, supra-sphincteric fistulas, extra-sphincteric fistulas, horseshoe fistulas or fistulas involving multiple tracts, anal fistulas associated with inflammatory bowl disease, radiation, malignancy, preexisting fecal incontinence or chronic diarrhea. While treatments in one stage (including fistulotomy (laying open the fistula tract) and fistulectomy (excision of the fistula tract) have shown an acceptable benefit (healing) / risk (incontinence) balance for the treatment of simple fistulas and have become the treatment of choice, there is a risk of incontinence in up to 80 % of patients with a complex fistula after one stage treatment. Alternative "sphincter-saving techniques" have been developed. However, none have shown evidence of superiority in terms of healing rate or anal incontinence. It therefore seems appropriate to develop new treatment alternatives for patients with a complex anal fistula. The clinical investigation is designed to evaluate the global healing rate of complex anal fistulas after radiofrequency procedure using the Fistura® procedure. Healing rate will be evaluated clinically and by performing an MRI. Secondary outcomes include healing rate per type of fistulas, assessment of anal incontinence, energy used and duration of the procedure, return to daily activities and work, quality of life and postoperative complications.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Braine l'Alleud, Belgium, 1420
        • CHIREC site Braine l'Alleud-Waterloo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with complex fistulas.

Complex fistulas include trans-sphincteric fistulas involving more than 30 % of the external sphincter, supra-sphincteric fistulas, extra-sphincteric fistulas, horseshoe fistulas or fistulas involving multiple tracts (according to the ASCRS) for which:

  • Suppuration is described by the patient and/or visible by an opening in the anal margin or by anoscopy
  • Clinical symptoms led to an MRI demonstrating the path
  • Fistula path demonstrated in the acute phase during drainage of an abscess

    • Patient ≥ 18 years at study entry
    • Patients with a previously drained fistula, without diverticula > 10 mm, without T2 hyperintensity (assessed by MRI). Drainage is achieved by placing a seton from 10 weeks to 12 months prior to the procedure.
    • Patient and investigator signed and dated the informed consent form prior to the procedure

Exclusion Criteria:

  • Patient < 18 years at study entry
  • Patient has a known contraindication to treatment using radiofrequency (infectious anal pathologies, anal fissures, residual Longo anterior treatment staples)
  • Patient has a known contraindication to MRI
  • Simple fistulas defined as inter-sphincteric or trans-sphincteric, involving less than 30 % of the total height of the sphincter apparatus (attested by MRI, ASCRS classification)
  • Patient has a fistula associated with radiation and inflammatory bowel disease
  • Patient is unable/unwilling to provide informed consent
  • Patient is unable to comply with the protocol or proposed follow-up visits and questionnaires
  • Patient is currently participating in another clinical study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fistura procedure
Adults participants with complex anal fistulas.

The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®) (both CE-marked).

The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. To allow closure, the tip of the catheter will heat the fistula and cause coagulation. The thermal effect around the catheter tip has a 3 mm radius, avoiding damage to surrounding tissue or muscle. The catheter is available in different sizes depending on the diameter of the anal fistula (6F, 7F, 8F, 9F). One Fistura® catheter will be used per patient, a total of 50 Fistura® catheters in this study.

As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global healing rate, clinically and MRI-assessed, at 12 months during an in-hospital visit
Time Frame: 12-month
Healing is defined as internal and external orifices obliteration without inflammation or discharge.
12-month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Healing rate per type of fistulas treated.
Time Frame: 12 months
Types of fistulas include trans-sphincteric fistulas involving more than 30 % of the external sphincter, supra-sphincteric fistulas, extra-sphincteric fistulas, horseshoe fistulas or fistulas involving multiple tracts
12 months
Healing rate without anal incontinence at 12 months
Time Frame: 12 months
12 months
Mean amount of energy used per treatment
Time Frame: Procedure
Procedure
Duration of the procedure
Time Frame: Procedure
Procedure
Return to daily activities
Time Frame: 2 weeks
Days to return to daily activities
2 weeks
Return to work
Time Frame: 2 weeks
Days to return to work
2 weeks
Rate and nature of late and immediate postoperative complications.
Time Frame: Procedure, 2 weeks, 2 months, 6 months, 12 months
Complications are defined as the number of adverse events related to the treatment and with abnormal MRI values
Procedure, 2 weeks, 2 months, 6 months, 12 months
Anal incontinence
Time Frame: 2 weeks, 2 months, 6 months, 12 months
Measured by the standard index of Jorge and Wexner. This score ranges from 0/20 for a perfect anal continence to 20/20 for a total incontinence. For scores above 10/20, the incontinence is considered severe.
2 weeks, 2 months, 6 months, 12 months
Quality of life
Time Frame: 2 weeks, 2 months, 6 months, 12 months
Measured by the Quality of Life Anal Fistula Questionnaire (QOLAF-Q) score. Measures quality of life in people with anal fistula and its score range is the following: zero impact=14 points, limited impact=15 to 28 points, moderate impact=29 to 42 points, high impact=43 to 56 points, and very high impact=57 to 70 points.
2 weeks, 2 months, 6 months, 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 15, 2023

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

June 2, 2023

First Submitted That Met QC Criteria

June 2, 2023

First Posted (Actual)

June 12, 2023

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Complex Anal Fistulas

Clinical Trials on Fistura® Procedure

3
Subscribe